Stem Cell Therapy for Refractory Angina

Refractory angina is chest pain from coronary artery disease that persists despite maximal medication and after a patient has run out of options for bypass surgery or stenting. For this specific, hard-to-treat population, a stem cell approach using the patient's own CD34+ cells has produced some of the most encouraging randomized trial data in the entire field — including a real mortality benefit. This article explains how the approach works, what the pooled trial data actually show, and who might be a candidate.

How It's Thought to Work

CD34+ cells are a type of blood-forming (hematopoietic) stem and progenitor cell, most commonly harvested from a patient's own bone marrow or mobilized into the bloodstream with a growth-factor medication and then collected. In this therapy, the cells are injected directly into the heart muscle (an intramyocardial injection, usually guided by a mapping catheter) in areas affected by poor blood flow. The working theory is that CD34+ cells support the formation of new small blood vessels (angiogenesis) in the oxygen-starved heart tissue, improving blood supply to the heart muscle and reducing the chest pain triggered by exertion.

What the Evidence Shows

The strongest evidence comes from a 2018 patient-level pooled analysis, published in the European Heart Journal, that combined three double-blinded, placebo-controlled randomized trials (a Phase 1 study, ACT34-CMI, and RENEW) totaling 304 patients with no-option refractory angina. Patients who received autologous CD34+ cell injections showed meaningfully longer total exercise time than those who received a placebo injection — an improvement of roughly 45-50 seconds at 3, 6, and 12 months (statistically significant at 3 and 6 months, and borderline at 12). Angina frequency was also significantly lower in the treated group at every time point measured. The most striking finding was on survival: at 24 months, all-cause mortality was 2.5% in the CD34+ group versus 12.1% in the placebo group, a statistically significant difference (P=0.0025). The pooled analysis also concluded the approach was safe, with no major safety concerns identified across the combined trials. These are genuinely strong results for a notoriously difficult-to-treat patient population that, by definition, has already exhausted standard interventional and surgical options. That said, this remains an investigational therapy: it has not received FDA approval, the pooled patient number (304) is still modest by drug-approval standards, and larger confirmatory Phase 3 data would typically be expected before any approval decision.

Who Might Be a Candidate

• This therapy is intended specifically for "no-option" refractory angina — patients with coronary artery disease causing significant chest pain who are not eligible for further bypass surgery or angioplasty/stenting and remain symptomatic despite optimal medical therapy
• It is not currently FDA-approved, so access today is through clinical trials; patients should search ClinicalTrials.gov for actively enrolling studies of CD34+ or other autologous cell therapies for refractory angina
• Candidates in the pooled trials underwent a bone marrow or blood stem cell collection procedure and a subsequent cardiac catheterization for the cell injections, so overall cardiovascular fitness for those procedures matters for eligibility
• Patients should discuss any interest in this approach with their cardiologist, since refractory angina management otherwise involves a range of medical and device-based options that should be exhausted or considered first
• As with any advanced cardiac condition, verifying a specific trial's registration and sponsor directly, rather than relying on a clinic's marketing claims, remains essential

Bottom Line

Stem cell therapy for refractory angina is one of the more genuinely promising, statistically rigorous stories in regenerative cardiology — a real, significant mortality difference in a pooled analysis of multiple randomized, placebo-controlled trials is not something this field produces often. It is not yet an approved treatment, and the number of patients studied, while unusually strong for this stage of development, is still well short of what regulators typically require before approval. For appropriately selected patients who have run out of standard options, though, this is a serious, evidence-backed avenue worth discussing with a cardiologist and pursuing through a registered clinical trial.